Shandong Weigao Group Medical Polymer Company Limited (WEIGAO GROUP) reported a further share buyback on 20 April 2026, according to its Next Day Disclosure Return filed with the Hong Kong Stock Exchange.

WEIGAO GROUP repurchased 200,000 H-shares on-market at prices ranging from HKD 3.68 to HKD 3.70, spending HKD 0.74 million. The transaction represents 0.0045 % of the company’s issued shares (excluding treasury stock) prior to the repurchase. All repurchased shares have been retained as treasury shares; none have been cancelled.

Following the buyback, outstanding shares (excluding treasury) stand at 4.47 billion, while treasury shares rise to 51.95 million. Total issued share capital remains unchanged at 4.52 billion shares.

The purchase forms part of the mandate approved on 27 May 2025, which authorises repurchases of up to 451.56 million shares. Cumulative repurchases under this mandate now total 45.30 million shares, equal to 10.03 % of the share count at the mandate date, leaving capacity for a further 406.26 million shares.

Under Main Board Rule 10.06, WEIGAO GROUP is subject to a moratorium on issuing new shares or disposing of treasury shares until 21 May 2026.